Film-Shaped Medicament for Oral Administration Containing Estriol
    11.
    发明申请
    Film-Shaped Medicament for Oral Administration Containing Estriol 审中-公开
    包含爱斯基摩人的口服药片

    公开(公告)号:US20070243217A1

    公开(公告)日:2007-10-18

    申请号:US11596239

    申请日:2005-05-06

    IPC分类号: A61K9/00

    CPC分类号: A61K31/565 A61K9/006

    摘要: Film-shaped medicaments administered orally, particularly buccally, for treating climacteric complaints. The medicaments contain estriol and/or at least one pharmacologically acceptable ester of estriol, either alone or in combination with at least one gestagen.

    摘要翻译: 经口给药,特别是口腔用药,用于治疗更年期的投诉。 药物含有雌三醇和/或至少一种药理学上可接受的雌三醇酯,单独或与至少一种孕激素组合。

    D-homo-(16-ene)-11.beta.-aryl-4-estrenes, process for their production
as well as their use as pharmaceutical agents
    18.
    发明授权
    D-homo-(16-ene)-11.beta.-aryl-4-estrenes, process for their production as well as their use as pharmaceutical agents 失效
    D-均聚(16-烯)-11β-芳基-4-雌酮,其制备方法以及作为药剂的用途

    公开(公告)号:US5519027A

    公开(公告)日:1996-05-21

    申请号:US78326

    申请日:1994-02-25

    CPC分类号: C07J63/008

    摘要: New D-homo-(16-ene)-11.beta.-aryl-4-estrenes of general formula I ##STR1## as well as their pharmaceutically compatible addition salts with acids are described in whichX stands for an oxygen atom, the hydroxyimino grouping >N.about.OH or two hydrogen atoms,R.sup.1 stands for a hydrogen atom or a methyl group,R.sup.2 stands for an hydroxy group, a C.sub.1 -C.sub.10 alkoxy or C.sub.1 -C.sub.10 acyloxy group,R.sup.11 stands for a fluorine, chlorine or bromine atom, and then R.sup.12 and R.sup.13 together mean an additional bond orR.sup.11 stands for a straight-chain or branched-chain C.sub.1 -C.sub.4 -alkyl radical or a hydrogen atom, and then R.sup.12 and R.sup.13 each mean a hydrogen atom or together mean an additional bond,and R.sup.3 and R.sup.4 have the usual meanings indicated in the description for competitive progesterone antagonists.The invention further relates to a process for the production of new compounds, pharmaceutical preparations containing these compounds, their use for the production of pharmaceutical agents as well as the new intermediate products necessary for the process.The new compounds have a strong affinity to the gestagen receptor and show strong antigestagen as well as antiglucocorticoid, antimineral corticoid and antiandrogenic properties.

    摘要翻译: PCT No.PCT / EP91 / 02495 371日期1994年2月25日 102(e)1994年2月25日PCT PCT 1991年12月21日PCT公布。 出版物WO92 / 11279 日期:1992年7月9日。通式I(I)的新型D-均 - (16-烯)-11β-芳基-4-雌酮及其与酸的药学上相容的加成盐描述于其中 X表示氧原子,羟基亚氨基> N不同OH或两个氢原子,R1表示氢原子或甲基,R2表示羟基,C1-C10烷氧基或C1-C10酰氧基,R11 代表氟,氯或溴原子,然后R 12和R 13一起表示另外的键或R 11表示直链或支链的C 1 -C 4烷基或氢原子,则R 12和R 13各自表示 氢原子或一起表示另外的键,并且R3和R4具有在竞争性孕酮拮抗剂的描述中指出的通常含义。 本发明还涉及生产新化合物的方法,含有这些化合物的药物制剂,其用于生产药物的用途以及该方法所需的新的中间产物。 新化合物对孕激素受体具有强烈的亲和力,并显示出强的抗老化,以及抗糖皮质激素,抗癫痫皮质激素和抗雄激素的特性。

    14.alpha.,17.alpha.-ethanoestratrienes
    20.
    发明授权
    14.alpha.,17.alpha.-ethanoestratrienes 失效
    14(ALPHA),17(ALPHA)-ETHANOESTRATRIENES

    公开(公告)号:US5134136A

    公开(公告)日:1992-07-28

    申请号:US679043

    申请日:1991-05-13

    IPC分类号: A61K31/565 C07J53/00

    CPC分类号: C07J53/002

    摘要: ##STR1## New 14α,17α-ethano-estratrienes of general formula (I) wherein R
    1 is a hydrogen atom, an alkyl or acyl group with 1 to 12 carbon atoms, R
    2 is a hydrogen atom or a methyl group, R
    3 is a hydrogen atom or an acyl group with 1 to 12 carbon atoms and (a) is either (II) or (III), where R
    4 is an alkyl residue in the α or β position with 1 to 8 carbon atoms or an α,β-alkenyl residue which may contain several double bonds or an α,β-alkinyl residue, both with 2 to 8 carbon atoms, are described. Also described is a process for producing them. These new compounds have a marked oestrogenic activity.

    摘要翻译: PCT No.PCT / DE89 / 00712 Sec。 371日期1991年5月13日 102(e)日期1991年5月13日PCT提交1989年11月10日PCT公布。 出版物WO90 / 05139 (III)新型14α,17α-通式(I)的α-甲基 - 雌三烯,其中R 1为(C 1 -C 6) 氢原子,具有1至12个碳原子的烷基或酰基,R 2是氢原子或甲基,R 3是氢原子或具有1至12个碳原子的酰基,和(a)是(II)或 (III),其中R4是具有1至8个碳原子的α或β位的烷基残基或可以含有几个双键的α,β-链烯基残基或α,β-链烯基残基,其中2至8个 碳原子。 还描述了它们的生产方法。 这些新化合物具有明显的雌激素活性。